Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group.

Dinutuximab plus sargramostim with COG induction cycles 3–5 was feasible and tolerable in 40 newly diagnosed high-risk neuroblastoma patients, with 92.0%–101.8% of planned DIN doses delivered.

• Why it matters: Adding dinutuximab to postconsolidation therapy improved event-free survival, but giving chemoimmunotherapy during induction needed multicenter tolerability and feasibility confirmation.
• What they did: In COG ANBL17P1, a prospective single-arm pilot, patients received DIN and sargramostim with induction cycles 3–5; tolerability was judged by predefined unacceptable toxicity/toxic death, and feasibility by receiving ≥75% of planned DIN doses.
• The result: No unacceptable toxicities or toxic deaths occurred during induction cycles 3–5, and the most common grade ≥3 DIN-related toxicities were fever (30.0%) and pain (7.5%); end-of-induction CR+PR was 87.5% and 3-year EFS was 52.5% ± 7.9%.

AI summary of the abstract · may contain errors · not medical advice · read the paper.